Hilltop Biosciences has filed a notice of an exempt offering of securities to raise $1,000,000.00 in Debt Financing.
Mansfield, MA – According to filings with the U.S. Securities and Exchange Commission, Hilltop Biosciences is raising $1,000,000.00 in new funding. Sources indicate as part of senior management President, Amanda Drobnis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Hilltop Biosciences
Hilltop Bio products are room temperature and off the shelf therapies that contain the whole orchestra of components that literature has shown helps up-regulate the bodies own immune response and aids in the healing process. Our products contain extracellular vesicles, growth factors, exosomes, cytokines, microRNA, and extracellular matrix that literature has shown to be effective to minimize inflammation and promote healthy tissue healing.
To learn more about Hilltop Biosciences, visit http://www.hilltopbiosciences.com/
Contact:
Amanda Drobnis, President
617-237-0636
https://www.linkedin.com/in/amanda-drobnis/
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved